Get the Stockscreener App
0.00
100.00%
-4.26
Checkpoint Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
See More
Previous Close:
$4.26
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$364.61M
Revenue:
$103.00K
Net Income/Loss:
$-42.47M
P/E Ratio:
0.00
EPS:
-1.9
Net Cash Flow:
$-34.30M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$4.50
Checkpoint Therapeutics Inc Stock (CKPT) Company Profile
Name
Checkpoint Therapeutics Inc
Sector
Industry
Phone
781-652-4500
Address
95 SAWYER ROAD, WALTHAM, NY
Compare CKPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CKPT
Checkpoint Therapeutics Inc
|
0.00 | 364.61M | 103.00K | -42.47M | -34.30M | -1.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Checkpoint Therapeutics Inc Stock (CKPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Jul-14-22 | Resumed | B. Riley Securities | Buy |
| Jun-09-21 | Initiated | B. Riley Securities | Buy |
| Jan-20-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-19 | Initiated | Lake Street | Buy |
| Dec-08-17 | Initiated | H.C. Wainwright | Buy |
View All
Checkpoint Therapeutics Inc Stock (CKPT) Latest News
What makes Checkpoint Therapeutics Inc. stock price move sharplyFree Stock Market Mentorship - Jammu Links News
What analysts say about Checkpoint Therapeutics Inc. stockCapitalize on fast-moving stock trends - Jammu Links News
Is Checkpoint Therapeutics Inc. a good long term investmentUnbelievable profit margins - Jammu Links News
What are analysts’ price targets for Checkpoint Therapeutics Inc. in the next 12 monthsExpert guidance for superior capital growth - Jammu Links News
Is Checkpoint Therapeutics Inc. stock overvalued or undervaluedUnlock powerful stock screening techniques - Jammu Links News
What are the latest earnings results for Checkpoint Therapeutics Inc.Achieve consistent profits with expert advice - Jammu Links News
What is the risk reward ratio of investing in Checkpoint Therapeutics Inc. stockMaximize gains with data-driven stock picks - Jammu Links News
What is Checkpoint Therapeutics Inc. company’s growth strategyFree Buy/Sell Signal Notifications - Jammu Links News
What drives Checkpoint Therapeutics Inc. stock priceIdentify undervalued stocks ready to soar - Jammu Links News
Published on: 2025-08-03 11:24:14 - Jammu Links News
What is the dividend policy of Checkpoint Therapeutics Inc. stockCapitalize on emerging investment opportunities - Jammu Links News
How does Checkpoint Therapeutics Inc. compare to its industry peersHigh-yield growth strategies - Jammu Links News
What are Checkpoint Therapeutics Inc. company’s key revenue driversRobust financial gains - Jammu Links News
How many analysts rate Checkpoint Therapeutics Inc. as a “Buy”Free Stock Updates For 2025 - Jammu Links News
How to integrate Checkpoint Therapeutics Inc. into portfolio analysis toolsEarly Entry Tips With Low Risk Zone Shared - metal.it
Quant Strategy Flags Checkpoint Therapeutics Inc. for EntryHigh Accuracy Alerts for ROI Traders Detected - beatles.ru
Checkpoint Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SaySafe Entry Stock Watch Suggestions for Cautious Traders - metal.it
Will Checkpoint Therapeutics Inc. rebound enough to break evenBreakout Confirmation With Entry Tracker Enabled - metal.it
How Checkpoint Therapeutics Inc. stock performs during market volatilityQuick Gain Stock Watch With Indicators Reviewed - beatles.ru
Investors Hope for Bounce in Checkpoint Therapeutics Inc. After SelloffAI Powered High Return Stock Calls Dominate Watchlists - metal.it
Technical Models Detect Momentum Build in Checkpoint Therapeutics Inc. - beatles.ru
Checkpoint Therapeutics Inc. Moves Into Overbought Range Analysts CautiousTarget Return Focused Trade Insights Shared - metal.it
Checkpoint Therapeutics Inc. Hits Price Floor — Bounce IncomingAI Powered High Return Stock Calls Dominate Watchlists - metal.it
What catalysts could drive Checkpoint Therapeutics Inc. stock higher in 2025Get expert analysis on top stock picks - Jammu Links News
Is Checkpoint Therapeutics Inc. a growth stock or a value stockMaximize your portfolio’s growth with expert tips - Jammu Links News
Does Checkpoint Therapeutics Inc. stock perform well during market downturnsRemarkable growth - Jammu Links News
How strong is Checkpoint Therapeutics Inc. company’s balance sheetChart Pattern Trend Scanner With Low Risk - Jammu Links News
When is Checkpoint Therapeutics Inc. stock expected to show significant growthDiscover high-impact investment opportunities - Jammu Links News
Published on: 2025-07-27 20:06:20 - Jammu Links News
What are the technical indicators suggesting about Checkpoint Therapeutics Inc.Outstanding capital appreciation - Jammu Links News
What institutional investors are buying Checkpoint Therapeutics Inc. stockPhenomenal investment performance - Jammu Links News
Published on: 2025-07-27 23:57:51 - Jammu Links News
Should I buy Checkpoint Therapeutics Inc. stock before earningsHigh-octane gains - Jammu Links News
Checkpoint Therapeutics Inc. Stock Analysis and ForecastSuperior stock selection - jammulinksnews.com
Checkpoint Therapeutics Completes Merger with Sun Pharma Subsidiary - MSN
Checkpoint Therapeutics Inc Stock (CKPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):